Giuseppe Bertuglia

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.

Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.

Journal: Frontiers in oncology

Published: March 03, 2026

Case Report: Iatrogenic dyspnea and respiratory failure in a multiple myeloma patient treated with carfilzomib.

Case Report: Iatrogenic dyspnea and respiratory failure in a multiple myeloma patient treated with carfilzomib.

Journal: Frontiers in oncology

Published: September 26, 2025

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Journal: ESMO open

Published: July 11, 2025

Peripheral monoclonal plasmacytosis in infective endocarditis: a tangled web.

Peripheral monoclonal plasmacytosis in infective endocarditis: a tangled web.

Journal: Haematologica

Published: May 21, 2025

Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.

Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.

Journal: Blood cancer discovery

Published: March 28, 2025

Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers.

Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers.

Journal: Blood cancer discovery

Published: March 28, 2025

Multiple Myeloma Unpacked.

Multiple Myeloma Unpacked.

Journal: Hematological oncology

Published: March 22, 2025

Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data.

Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data.

Journal: Haematologica

Published: January 07, 2025

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: November 22, 2024

M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone.

M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone.

Journal: British journal of haematology

Published: November 15, 2024

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

Journal: ESMO open

Published: October 12, 2024

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Journal: Haematologica

Published: September 15, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026